2022 World Conference on Lung Cancer (ePosters)-EP08.02-105. KRAS p.G12 Mutated Advanced Non-Small Cell Lung Cancer. Characteristics and Outcomes from a Danish Nationwide Observational Study

EP08.02-105. KRAS p.G12 Mutated Advanced Non-Small Cell Lung Cancer. Characteristics and Outcomes from a Danish Nationwide Observational Study

Back to course

Pdf Summary

This study analyzed the characteristics and overall survival of patients with KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Denmark. The researchers found that patients with KRAS G12C mutation had superior survival compared to those with any other KRAS mutation, triple wildtype (WT), and all NSCLC patients. This may be attributed to higher PD-L1 expression and more frequent use of anti-PD-1/PD-L1 treatment in the KRAS G12C group.<br /><br />The study also highlighted the high unmet need for patients with low (1%) and intermediate (1-49%) PD-L1 expression levels, as their survival was markedly shorter. The researchers found that survival for patients with KRAS G12C and PD-L1 1-49% was shorter compared to other groups, while survival was comparable among all patient groups with PD-L1 50%.<br /><br />KRAS G12C inhibitors are a novel targeted treatment for advanced NSCLC. The KRAS G12C mutation is common, occurring in approximately 13% of NSCLC patients. However, there is a lack of knowledge about the clinical outcomes associated with current standard of care for these patients.<br /><br />The study utilized data from the Danish Lung Cancer Register and other national registries to identify Danish adults diagnosed with advanced NSCLC between January 2018 and June 2021. The information collected included clinical and demographic data.<br /><br />In conclusion, this observational study indicates that patients with KRAS G12C mutated NSCLC have superior survival compared to other KRAS mutation groups and all NSCLC patients. However, further research is needed to understand the clinical outcomes associated with different treatment approaches for KRAS G12C mutated NSCLC patients with low and intermediate PD-L1 expression levels.

Asset Subtitle

Matilde Tejlbo Frost

Meta Tag

Speaker Matilde Tejlbo Frost

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

KRAS G12C mutated

advanced non-small cell lung cancer

NSCLC

Denmark

overall survival

KRAS mutation

triple wildtype

PD-L1 expression

anti-PD-1/PD-L1 treatment

unmet need